VANCOUVER, British Columbia, April 14, 2026 (GLOBE NEWSWIRE) -- MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) (the “Company” or “MindBio”) has appointed Venture Liquidity Providers Inc. (VLP) as its market maker, effective April 14, 2026. The appointment is intended to enhance trading liquidity and market efficiency for the company's publicly traded shares.
VLP will conduct market-making activities in compliance with the policies of the Canadian Securities Exchange (CSE) and other applicable regulations. The agreement is for an initial term of three months and will automatically renew for successive one-month terms unless terminated by either party with 30 days' notice.
MindBio is a biotechnology company focused on developing psychedelic-inspired medicines. The company's research includes clinical trials investigating microdosed LSD for the treatment of conditions such as Major Depressive Disorder. The engagement of a market maker is a common corporate practice aimed at providing more consistent bid-ask spreads and trading volume for investors.
No specific financial terms of the agreement were disclosed in the company's announcement. The market-making services are to be funded from the company's working capital.
